Murtaza Fahmeeda, Toameh Dana, Al-Habib Saed, Maini Raj, Chiu Hannah H, Tam Eric S, Somani Sohel
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Uptown Eye Specialists, Brampton, Ontario, Canada.
Clin Ophthalmol. 2021 Oct 2;15:3983-3991. doi: 10.2147/OPTH.S331289. eCollection 2021.
BroadBand light intense pulsed light (BBL-IPL) therapy has shown to reduce hordeolum and blepharitis frequency. This study aims to evaluate the efficacy and safety of BBL-IPL therapy in patients with dry eye disease (DED) from meibomian gland dysfunction (MGD).
This is a retrospective, consecutive case series of 48 patients with DED from MGD who underwent BBL-IPL therapy from October 2016 to January 2019 at a single, outpatient clinic in Ontario, Canada. Clinical outcomes included first and average non-invasive keratograph tear break-up times (NIKBUT), bulbar redness (BR) scores, tear meniscus heights (TMH), visual acuity (VA) and meibograph grades. Patient-reported outcomes included the Canadian dry eye assessment (CDEA) questionnaire and patient subjective assessment (PSA) scores. Outcomes were measured at baseline and after completion of 4 monthly BBL-IPL sessions.
The mean severity of dry eye symptoms as measured by the CDEA and PSA decreased significantly from 19.78 ± 9.62 to 12.08 ± 7.40 (<0.001) and from 7.65 ± 1.74 to 4.77 ± 2.03 (<0.001), respectively. Twenty-five percent of patients reported no dry eye symptoms after treatment. The meibograph grade improved significantly in both eyes (<0.001). Approximately 71.0% and 80.1% of patients had an improved meibograph grade in the right and left eye, respectively. Near-significant improvements were observed for BR scores and VA. There was also a trend towards improved first/average NIKBUT and TMH scores. No adverse events were noted.
BBL-IPL appears to be an effective and safe treatment modality in improving dry eye symptoms and meibomian gland function in patients with DED from MGD.
强脉冲光（BBL-IPL）治疗已被证明可降低睑腺炎和睑缘炎的发病率。本研究旨在评估BBL-IPL治疗睑板腺功能障碍（MGD）所致干眼疾病（DED）患者的疗效和安全性。
这是一项回顾性、连续性病例系列研究，纳入了2016年10月至2019年1月期间在加拿大安大略省一家门诊诊所接受BBL-IPL治疗的48例MGD所致DED患者。临床结局包括首次和平均非侵入性角膜地形图泪膜破裂时间（NIKBUT）、球结膜充血（BR）评分、泪河高度（TMH）、视力（VA）和睑板腺造影分级。患者报告的结局包括加拿大干眼评估（CDEA）问卷和患者主观评估（PSA）评分。在基线时以及完成4次每月一次的BBL-IPL治疗后测量结局。
通过CDEA和PSA测量的干眼症状平均严重程度分别从19.78±9.62显著降低至12.08±7.40（<0.001）和从7.65±1.74显著降低至4.77±2.03（<0.001）。25%的患者在治疗后报告无干眼症状。双眼睑板腺造影分级均显著改善（<0.001）。分别约71.0%和80.1%的患者右眼和左眼睑板腺造影分级得到改善。BR评分和VA观察到接近显著的改善。首次/平均NIKBUT和TMH评分也有改善趋势。未观察到不良事件。
BBL-IPL似乎是一种有效且安全的治疗方式，可改善MGD所致DED患者的干眼症状和睑板腺功能。
